After overcoming recent challenges, Gongwin Biopharm Holdings Co Ltd (共信生醫) expects to apply for a debut on the Taipei Exchange before the end of the third quarter and gain market approval for its new lung cancer drug in the Chinese market before the end of the year.
The company’s PTS302, a minimally invasive chemical ablation agent that is injected directly into malignant lung cancer tumors, is undergoing a safety review on raw materials and manufacturing processes by the Chinese Center for Drug Evaluation, reaching one of the final stages of the approval process, Gongwin general manager Morris Lin (林懋元) told the Taipei Times in an interview on March 25.
However, prior to securing its place on Chinese regulators’ long-review list, the company’s bid was severely affected by rapid policy changes, as stricter standards drove many Chinese manufacturers of active pharmaceutical ingredients out of business, constraining supply of p-toluenesulfonamide, the key reagent used to make PTS-302.
That was a major stumbling block, as without a steady supply of the reagent, the company would not have been able to provide doses for clinical trials or prove to regulators that it was ready to enter mass production while meeting drug safety standards, Lin said.
The company averted a crisis by securing agreements with suppliers from foreign markets, Lin said, adding that it was a difficult process to find manufacturers capable of making the pharmaceutical-grade reagents it requires.
However, the company would benefit from a having a more diversified list of qualified suppliers, he said.
Gongwin, which is listed on the preparatory Emerging Stock Board, plans to be listed on the Taipei Exchange before the end of this year on the expectation that PTS302 would be approved for the Chinese market in the third quarter.
Overall, China’s review procedure has become more efficient as Beijing adopts internationally accepted harmonized standards, Lin said, adding that this would make the outcome of new drug applications more predictable.
The company would also benefit from a change in drug approval criteria that recognize the benefits of PTS302’s ability to promote tumor necrosis through chemical ablation, he said.
Prior to the change, regulators favored tumor size reduction, which was what chemotherapy drug infusions were designed to do, Lin said.
China remains the primary market for PTS302 due to high rates of lung diseases linked to air pollution and a large population of smokers.
“A solid revenue stream from an approved drug would make our initial public offering much more appealing to investors,” Lin said, adding that following upheavals in the past few years, Taiwan’s biotechnology investment environment has begun to recover from a dip in confidence.
Gongwin would stay in its home market, Lin said.
The company in May last year raised NT$297 million (US$9.64 million) via a capital increase, meeting the Taipei Exchange’s listing requirement for biotechnology companies, under which an applicant’s net value must not dip below two-thirds of its market capitalization.
Gongwin vice president Pierre Hsiao (蕭斯欣) said that due to the way PTS302 is administered, sales would need to be facilitated by a network of medical institutions and physicians who are familiar with the injection process.
The company in January announced a strategic investment in KingMed Smart Care (金域利安), China’s largest provider of clinical medical testing and pathology solutions, Hsiao said.
Such partnerships help cement Gongwin’s hold on its intended market segment and ward off generic drug makers, he said.
BUSINESS UPDATE: The iPhone assembler said operations outlook is expected to show quarter-on-quarter and year-on-year growth for the second quarter Hon Hai Precision Industry Co (鴻海精密) yesterday reported strong growth in sales last month, potentially raising expectations for iPhone sales while artificial intelligence (AI)-related business booms. The company, which assembles the majority of Apple Inc’s smartphones, reported a 19.03 percent rise in monthly sales to NT$510.9 billion (US$15.78 billion), from NT$429.22 billion in the same period last year. On a monthly basis, sales rose 14.16 percent, it said. The company in a statement said that last month’s revenue was a record-breaking April performance. Hon Hai, known also as Foxconn Technology Group (富士康科技集團), assembles most iPhones, but the company is diversifying its business to
ARTIFICIAL INTELLIGENCE: The chipmaker last month raised its capital spending by 28 percent for this year to NT$32 billion from a previous estimate of NT$25 billion Contract chipmaker Powerchip Semiconductor Manufacturing Corp (力積電子) yesterday launched a new 12-inch fab, tapping into advanced chip-on-wafer-on-substrate (CoWoS) packaging technology to support rising demand for artificial intelligence (AI) devices. Powerchip is to offer interposers, one of three parts in CoWoS packaging technology, with shipments scheduled for the second half of this year, Powerchip chairman Frank Huang (黃崇仁) told reporters on the sidelines of a fab inauguration ceremony in the Tongluo Science Park (銅鑼科學園區) in Miaoli County yesterday. “We are working with customers to supply CoWoS-related business, utilizing part of this new fab’s capacity,” Huang said, adding that Powerchip intended to bridge
Microsoft Corp yesterday said that it would create Thailand’s first data center region to boost cloud and artificial intelligence (AI) infrastructure, promising AI training to more than 100,000 people to develop tech. Bangkok is a key economic player in Southeast Asia, but it has lagged behind Indonesia and Singapore when it comes to the tech industry. Thailand has an “incredible opportunity to build a digital-first, AI-powered future,” Microsoft chairman and chief executive officer Satya Nadella said at an event in Bangkok. Data center regions are physical locations that store computing infrastructure, allowing secure and reliable access to cloud platforms. The global embrace of AI
Qualcomm Inc, the world’s biggest seller of smartphone processors, gave an upbeat forecast for sales and profit in the current period, suggesting demand for handsets is increasing after a two-year slump. Revenue in the three months ended in June will be US$8.8 billion to US$9.6 billion, the company said in a statement Wednesday. Excluding certain items, earnings will be US$2.15 to US$2.35 a share. Analysts had projected sales of US$9.08 billion and earnings of US$2.16 a share. The outlook signals that the smartphone market has begun to bounce back, tracking with Qualcomm’s forecast that demand would gradually recover this year. The San